What kind of company is Nasonex?

Company Profile: Nasonex

Nasonex is a brand name for mometasone, a synthetic corticosteroid. Nasonex nasal spray is used to treat allergy symptoms such as sneezing, congestion, and a runny nose caused by indoor and outdoor allergens. It is also used to treat nasal polyps in adults.

Nasonex is manufactured by Merck & Co., a multinational pharmaceutical company. The brand is distributed in the United States by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co. Nasonex is also available in other countries under different names.

Nasonex was first approved by the United States Food and Drug Administration (FDA) in 1997 for the treatment of seasonal and perennial allergic rhinitis in adults and children six years and older. Later, it got approved for the treatment of nasal polyps in adults.

Products

Nasonex's main product is the mometasone nasal spray, which is available only through prescription. The nasal spray comes in two strengths, 50 mcg and 100 mcg, and is indicated for the treatment of seasonal and perennial allergic rhinitis and nasal polyps.

Company History

Merck & Co. began developing mometasone nasal spray in the 1980s and received FDA approval in 1997. Merck Sharp & Dohme began distributing Nasonex in the United States in 2001.

In 2007, Merck and Schering-Plough announced a joint venture in which Merck would acquire Schering-Plough. The merger was completed in 2009, and Nasonex became a Merck product.

Conclusion

Nasonex is a prescription nasal spray used for treating allergy symptoms and nasal polyps. The brand is owned by Merck & Co. and distributed in the United States by Merck Sharp & Dohme Corp. Nasonex is a well-established product in the allergy medication market, enjoying significant popularity among physicians and patients alike.